A prospective study of comprehensive genomic testing to identify actionable variants in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).

• DOI: 10.1200/jco.2024.42.4_suppl.185
• Publication Date: 2024-01-29T21:06:41Z
• Authors: Daniel Shevrin; Mathew Yang; Linda Sabatini; Nicklas Pfanzelter; Michael Akroush; Hussein Alnajar; Larry Helseth
• Keywords: 03 medical and health sciences; 0302 clinical medicine

185 Background: Genomic testing in pts with mCRPC has become an important tool to identify actionable variants, particular on-label treatment recommendation. Testing previously required tumor tissue, but cfDNA is now approved as a companion diagnostic for specific HRR variants. In this prospective study at community-based hospital, we conducted comprehensive genomic We report results on variants specifically Methods: Pts had using the PredicineCare NGS assay and germline tissue (archival metastasis when available) NorthShore Expanded Cancer Panel. Sequence data were entered into Flype, our in-house software used secondary analysis, annotation of results, sign-out. Clinical outcomes obtained structured note selected discussed molecular board. Results: Of 108 enrolled pts, all testing. Results from 48 19, 22, both 7). Overall, 42 (38%) 1 or more recommendation treatment. these, 40 (BRCA1/2 ATM 7, CHEK2 in12, CDK12 3, other 2) 2 MSI-H. 19 BRCA1/2 reported, 14 deletions detected by cfDNA. Treatment was recommended 7 these whose done after there change level evidence supporting The reported prior are included total. Repeat 16 progression new variant pts. They recommendation, 23 (56%) have received treatment, PARP inhibitor 4 pembrolizumab. detecting 68%, 16%, 16%. Conclusions: study, 38% identified highlighting value relatively high number testing, alone 68% emphasizing complement alternative cohort almost half tested, potential serial progression. As report, 56% drug clinical being evaluated. potentially evaluated off-label trials.